<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Dabigatran etexilate</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06695</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Dabigatran etexilate is an oral prodrug that is metabolized by a serum esterase to dabigatran. It is a synthetic, competitive and reversible direct thrombin inhibitor. Inhibition of thrombin disrupts the coagulation cascade and inhibits the formation of clots. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients who have undergone total hip or knee replacement surgery, or to prevent stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation therapy is indicated. In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary. <span class="caps">FDA</span> approved on October 19, 2010.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06695/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06695/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06695.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06695.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06695.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06695.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06695.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06695">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Dabigatran </td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ethyl 3-[[[4-[[[(hexyloxyl)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino] propanoate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Dabigatran etexilate mesilate </strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000035/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000035/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: XETBXHPXHHOLOE-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 723.305032141</li>
              <li>Average Mass: 723.839</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000035">DBSALT000035</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Pradax</td><td>Boehringer Ingelheim</td></tr><tr><td>Pradaxa</td><td>Boehringer Ingelheim</td></tr><tr><td>Rendix</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antithrombins">Antithrombins</a></li></ul></td></tr><tr><th>CAS number</th><td>211915-06-9</td></tr><tr><th>Weight</th><td>Average: 627.7332<br>Monoisotopic: 627.316917457</td></tr><tr><th>Chemical Formula</th><td>C<sub>34</sub>H<sub>41</sub>N<sub>7</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>KSGXQBZTULBEEQ-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C34H41N7O5/c1-4-6-7-10-21-46-34(44)39-32(35)24-12-15-26(16-13-24)37-23-30-38-27-22-25(14-17-28(27)40(30)3)33(43)41(20-18-31(42)45-5-2)29-11-8-9-19-36-29/h8-9,11-17,19,22,37H,4-7,10,18,20-21,23H2,1-3H3,(H2,35,39,44)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">ethyl 3-(1-{2-[({4-[amino({[(hexyloxy)carbonyl]imino})methyl]phenyl}amino)methyl]-1-methyl-1H-1,3-benzodiazol-5-yl}-N-(pyridin-2-yl)formamido)propanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCCCCCOC(=O)N=C(N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=CC=CC=N3)N2C)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzimidazoles</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzimidazoles</td></tr><tr><th>Alternative parents</th><td>Benzamides; Benzoyl Derivatives; Aminopyridines and Derivatives; Dicarboxylic Acids and Derivatives; N-substituted Imidazoles; Tertiary Carboxylic Acid Amides; Carboxylic Acid Esters; Tertiary Amines; Ethers; Carboxylic Acids; Carboxamidines; Secondary Amines; Polyamines; Enolates</td></tr><tr><th>Substituents</th><td>benzoyl; aminopyridine; dicarboxylic acid derivative; pyridine; benzene; n-substituted imidazole; azole; imidazole; tertiary carboxylic acid amide; carboxamide group; tertiary amine; carboxylic acid ester; amidine; ether; polyamine; carboxylic acid; enolate; secondary amine; carboxylic acid amidine; carboxylic acid derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzimidazoles. These are organic compounds containing a benzene ring fused to an imidazole ring (five member ring containing a nitrogen atom, 4 carbon atoms, and two double bonds).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Dabigatran is indicated for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery (based on RE-NOVATE, RE-MODEL, and RE-MOBILIZE trials). In 2010, it was approved in the US and Canada for prevention of stroke and systemic embolism in patients with atrial fibrillation (approval based on the RE-LY trial). Contraindications: severe renal impairment (CrCL </td></tr><tr><th>Pharmacodynamics</th><td>Dabigatran directly inhibits thrombin in a concentration-dependent, reversible, specific, and competitive manner which results in a prolongation of aPTT (partial thromboplastin time), ECT (Ecarin clotting time), and TT (thrombin time). It may increase INR but this laboratory parameter is relatively insensitive to the activity of dabigatran.  </td></tr><tr><th>Mechanism of action</th><td>Dabigatran etexilate is an inactive pro-drug that is converted to dabigatran, the active form, by esterase-catalyzed hydrolysis in the plasma and liver. Dabigatran, the main active principle in plasma, is a rapid-acting competitive and reversible direct inhibitor of thrombin. Thrombin, a serine protease, is responsible for the conversion of fibrinogen to fibrin in the coagulation cascade. Inhibition of thrombin consequently prevents thrombus development. Dabigatran inhibits free thrombin, fibrin-bound thrombin and thrombin-induced platelet aggregation.</td></tr><tr><th>Absorption</th><td>Peak plasma concentrations were achieved in 6 hours in post surgical patients. In healthy patients, maximum concentrations were achieved in 0.5 to 2 hours. The absolute bioavailability of dabigatran in the body after administration of dabigatran etexilate was 6.5%. Food does not affect the bioavailability of dabigatran etexilate, but it delays the time to peak plasma concentrations by 2 hours. Oral bioavailability may increase by up to 75% when pellets are taken out of the hydroxypropylmethylcellulose (HPMC) capsule. Therefore, capsules should not be opened and pellets taken alone. Furthermore, although absorption of dabigatran etexilate is independent of gastrointestinal acidity, coadministration of pantoprazole (proton pump inhibitor) may reduce the bioavailability of dabigatran. Despite this finding, dose adjustment is not required. </td></tr><tr><th>Volume of distribution</th><td><p>Moderate tissue distribution with a Vd of 60-70L. <br>
Accumulation factor, twice daily dosing = 2</p></td></tr><tr><th>Protein binding</th><td>Relatively low binding (34-35%) to plasma proteins. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>CYP450 enzymes are not involved in the metabolism of dabigatran thus is not expected to interact with drugs metabolized by CYP isoenzymes. Dabigatran is typically metabolised by esterases and microsomal carboxylesterases.  Pharmacologically active acylglucoronides are formed via conjugation. Four positional isomers, 1-O, 2-O, 3-O, and 4-O, acylglucuronides exist, each accounting for less than 10% of total plasma dabagatran. </p></td></tr><tr><th>Route of elimination</th><td>Mainly excreted in urine (85%). Fecal excretion accounts for 6% of the orally administered dose. Dabigatran is primarily eliminated unchanged via the kidneys at a rate of 100 ml/min corresponding to the glomerular filtration rate. </td></tr><tr><th>Half life</th><td>12-14 hours in healthy volunteers. 14-17 hours in patients treated for prevention of venous thromboembolism following hip- or knee-replacement surgery. </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The most common adverse reactions include dyspepsia or gastritis-like symptoms. The approximate lethal dose (LD50) in rats and mice was observed at single oral doses of &gt; 2000 mg/kg. Oral doses of 600 mg/kg did not induce any toxicologically meaningful changes in dogs and Rhesus monkeys. Dabigatran was well-tolerated in rats and Rhesus monkeys during repeat-dose toxicity studies. No evidence of mutagenic potential. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.942</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8673</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.7014</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7412</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7539</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8443</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.701</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.858</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.837</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6154</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6906</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5102</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8417</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5157</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.781</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5789</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6292
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8065
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9931
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7093 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9047
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.6181
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Boehringer ingelheim</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>110 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>150 mg</td></tr><tr><td>Capsule</td><td>Oral</td><td>75 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the serum concentration of dabigatran etexilate, resulting in increased risk of bleeding. Consider modifying therapy.</td></tr><tr><td><a href="/drugs/DB06605">Apixaban</a></td><td>Concomitant therapy with another anticoagulant may increase bleed risk. Monitor closely for adverse effects. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>P-Glycoprotein inducers such as carbamazepine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>P-Glycoprotein inducers such as dexamethasone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00997">Doxorubicin</a></td><td>P-Glycoprotein inducers such as doxorubicin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Dronedarone inhibits P-glycoprotein transporter thus increasing serum concentrations of dabigatran 1.1-1.9-fold. </td></tr><tr><td><a href="/drugs/DB01381">Ginkgo biloba</a></td><td>Additive anticoagulant/antiplatelet effects of gingko may increase bleed risk for patients on dabigatran. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Coadministration with a strong p-glycoprotein inhibitor may increase the level or effect of dabigatran. Monitor closely for adverse effects. </td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Dabigatran is a p-glycoprotien (P-gp) substrate. Levels of dabigatran may increase if coadministered with lomipatide, which is a P-gp inhibitor. Thus, it is recommended to dose reduce P-gp substrates (such as ambrisentan, aliskiren, colchicine, digoxin, everolimus, fexofenadine, imatinib, lapatinib, maraviroc, nilotinib, posaconazole, ranolazine, saxagliptin, sirolimus, sitagliptin, talinolol, tolvaptan, topotecan) with the concomitant use of lomipatide.  </td></tr><tr><td><a href="/drugs/DB00834">Mifepristone</a></td><td>May lead to excessive post-abortion bleeding in patients on anticoagulant therapy. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>P-Glycoprotein inducers such as nefazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00213">Pantoprazole</a></td><td>Proton pump inhibitors may decrease the bioavailability of dabigatran by 28% and increase inter-patient pharmacokinetic variability, especially in females. However, dose adjustment is not required. </td></tr><tr><td><a href="/drugs/DB00457">Prazosin</a></td><td>P-Glycoprotein inducers such as prazosin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Quinidine may increase the serum concentration of dabigatran etexilate, resulting in increased bleeding. Consider modification of therapy.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>P-Glycoprotein inducers such as rifampin may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB06228">Rivaroxaban</a></td><td>Using additional anticoagulants such as dabigatran can increase the anticoagulant effect of rivaroxaban. Avoid concurrent use of rivaroxaban with other anticoagulants whenever possible, other than during transition periods, due to the possible increased for bleeding. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>P-Glycoprotein inducers such as tipranavir may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>P-Glycoprotein inducers such as trazodone may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil may increase serum concentrations of the active metabolite(s) of dabigatran etexilate, resulting in an increased risk of bleeding. It is also a strong p-glycoprotein inhibitor. Therapy modification should be considered.</td></tr><tr><td><a href="/drugs/DB00570">Vinblastine</a></td><td>P-Glycoprotein inducers such as vinblastine may decrease the serum concentration of dabigatran etexilate. This combination should be avoided.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>St. John's Wort</li></ul></td></tr></tbody></table>